Revenue is expected to decline due to delayed revenue recognition for certain projects in the regenerative medicine support business. However, company-wide cost reductions keep operating income flat, and ordinary income and net income attributable to owners of parent are expected to show reduced deficit. The full-year guidance has been revised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7776","jir_company_name":"CellSeed Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7776-20261113-03.pdf","jir_short_summary":"Revenue is expected to decline due to delayed revenue recognition for certain projects in the regenerative medicine support business. However, company-wide cost reductions keep operating income flat, and ordinary income and net income attributable to owners of parent are expected to show reduced deficit. The full-year guidance has been revised.","jir_summary":"### Performance Summary\nThe earnings guidance for the fiscal year ending December 2026 has been revised. Revenue is expected to decline because revenue recognition for certain projects in the contract regenerative medicine business was deferred. Meanwhile, thorough company-wide cost reductions resulted in operating income remaining in line with the previous forecast, and ordinary income and net income attributable to owners of parent are expected to show narrower deficits.\n\n### Outlook and Points to Note\nNo foreign exchange information is provided, and results may fluctuate depending on future project developments. Note that net income per share has been adjusted from the previous forecast to reflect the exercise status of stock acquisition rights.","jir_financial_highlights":"Net Sales: Previous Forecast (A) 71 (Revised Forecast (B) 50)\nOperating Income: Previous Forecast (A) -1,225 (Revised Forecast (B) -1,225)\nOrdinary Income: Previous Forecast (A) -1,250 (Revised Forecast (B) -1,234)\nNet Income Attributable to Owners of Parent: Previous Forecast (A) -1,320 (Revised Forecast (B) -1,309)\nNet Income per Share: Previous Forecast (A) -30.51 yen (Revised Forecast (B) -33.81 yen)","jir_category":"","jir_hashtags":"Share Buyback, BoardPersonnel","jir_key_figures":"Net Sales: Previous Forecast 71 million yen \u2192 Revised Forecast 50 million yen\nOperating Income: -1,225 million yen (same as previous forecast)\nOrdinary Income: -1,250 million yen \u2192 -1,234 million yen\nNet Income Attributable to Owners of Parent: -1,320 million yen \u2192 -1,309 million yen\nNet Income per Share: -30.51 yen \u2192 -33.81 yen","jir_meta_title":"CellSeed Inc. Revises Earnings Guidance\uff5cFiscal Year Ending December 2026","jir_meta_description":"CellSeed Inc. revises its earnings guidance for the fiscal year ending December 2026. Summary of factors behind the revenue decline, mitigation of profit impact through cost reductions, and changes to earnings per share for investor reference.","jir_og_title":"CellSeed Inc.\uff5cRevision to Earnings Guidance for FY Dec 2026","jir_og_description":"Revenue outlook for regenerative medicine-related business has been revised downward, but expense reductions have limited the impact on profits. See the full text for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59075,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-153383","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n